$2.10 Million in Sales Expected for Aravive Inc (NASDAQ:ARAV) This Quarter

Equities research analysts expect Aravive Inc (NASDAQ:ARAV) to announce sales of $2.10 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Aravive’s earnings, with the highest sales estimate coming in at $3.19 million and the lowest estimate coming in at $1.00 million. Aravive posted sales of $1.37 million in the same quarter last year, which suggests a positive year over year growth rate of 53.3%. The company is expected to announce its next earnings report on Thursday, March 5th.

According to Zacks, analysts expect that Aravive will report full year sales of $7.38 million for the current financial year, with estimates ranging from $4.80 million to $10.60 million. For the next year, analysts expect that the company will post sales of $9.70 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Aravive.

Aravive (NASDAQ:ARAV) last announced its earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.04).

Several analysts have recently commented on ARAV shares. Zacks Investment Research cut Aravive from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. ValuEngine raised Aravive from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Piper Jaffray Companies set a $15.00 target price on Aravive and gave the stock a “buy” rating in a research report on Friday, September 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Aravive in a research report on Friday. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $13.69.

In related news, CEO Jay Shepard sold 4,004 shares of Aravive stock in a transaction on Monday, October 7th. The stock was sold at an average price of $6.82, for a total transaction of $27,307.28. 39.80% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARAV. Artal Group S.A. boosted its position in Aravive by 20.0% during the second quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock valued at $1,845,000 after purchasing an additional 51,197 shares during the last quarter. Renaissance Technologies LLC boosted its position in Aravive by 13.8% during the second quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock valued at $890,000 after purchasing an additional 18,017 shares during the last quarter. BlackRock Inc. boosted its position in Aravive by 5.8% during the second quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock valued at $1,044,000 after purchasing an additional 9,544 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Aravive by 4.7% during the second quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock valued at $955,000 after purchasing an additional 7,200 shares during the last quarter. 28.35% of the stock is owned by hedge funds and other institutional investors.

Aravive stock traded up $0.01 during mid-day trading on Thursday, hitting $6.53. 5,300 shares of the company’s stock traded hands, compared to its average volume of 23,717. The company has a market cap of $75.95 million, a PE ratio of -0.61 and a beta of 2.17. The firm has a 50 day moving average price of $7.03 and a 200 day moving average price of $6.27. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.17. Aravive has a one year low of $3.07 and a one year high of $9.72.

Aravive Company Profile

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Featured Story: What is an inverted yield curve?

Get a free copy of the Zacks research report on Aravive (ARAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aravive (NASDAQ:ARAV)

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.